X-twitter Linkedin Facebook-f Vimeo

Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

BIOG

Biotech Growth Trust portfolio company AtaiBeckley to be acquired by Eli Lilly

Eli Lilly’s proposed acquisition of AtaiBeckley values the biotechnology company at up to $3.8 billion, including contingent milestone payments. The transaction is the latest in a series of portfolio acquisitions..
EDX Medical Group

EDX Medical Group Targets More Than £2 Million From New Employee Health Screening Service (video)

Chief Scientific Officer Sir Chris Evans explains how its on-site testing model, multi-biomarker panels and personalised reports could help employers identify health risks earlier while reducing disruption and absenteeism...
EDX Medical Group plc

EDX Medical builds scale through Scottish Prostate Cancer Testing programme

EDX Medical is expanding its role in a 25,000-participant Scottish programme testing a more targeted approach to prostate cancer detection...
CTEC

Convatec names NED and outlines CFO transition

Convatec has outlined finance leadership changes, appointed Tobias Hestler as a Non-Executive Director and reaffirmed its 2026 expectations...
CIZ

Cizzle Biotechnology reports US accreditation and patent progress in H1 2026

Cizzle Biotechnology entered its commercialisation phase during the first half of 2026 after securing CLIA accreditation for its CIZ1B early lung cancer test in the U.S. The company also strengthened..
GNS

Genus expects FY26 profit ahead of consensus after stronger second half

Genus Plc says second-half trading improved, with stronger PIC and ABS performance, and now expects FY26 results moderately ahead of consensus...
BIOG

Biotech Growth Trust gains 19.2% in June, outperforms benchmark

The Biotech Growth Trust delivered a 19.2% NAV return in June, ahead of the NASDAQ Biotechnology Index’s 11.4% gain, supported by positive clinical, regulatory and M&A developments across the sector...
SPI

Spire Healthcare names Debbie White as Chair-designate ahead of Sir Ian Cheshire’s departure

Spire Healthcare has announced that Sir Ian Cheshire will step down as Chair by 30 September 2026 and Debbie White will succeed him...
AstraZeneca

Astrazeneca secures global rights to Zegfrovy in EGFR-mutated lung cancer

Astrazeneca Plc has agreed an exclusive licence with Dizal Pharmaceutical for Zegfrovy, adding a novel oral EGFR inhibitor to its oncology portfolio...
GENF

Genflow Biosciences reports continued SIRT6 progress in first half of 2026

Genflow Biosciences reported positive interim and three-month follow-up results from its SLAB canine trial, expanded animal health partnerships, secured a fully funded LNP collaboration with Acuitas Therapeutics and strengthened its..
GSK plc

GSK reports positive interim AZUR-1 results for Jemperli in rectal cancer

GSK has reported positive interim AZUR-1 results for Jemperli in dMMR/MSI-H locally advanced rectal cancer, with the study meeting its primary objective...
AstraZeneca

AstraZeneca and Ionis’ Wainua misses Phase III ATTR-CM trial endpoint

The CARDIO-TTRansform Phase III trial1 for AstraZeneca and Ionis' Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy.....
Biotech Growth Trust

Biotech Growth Trust: The biotech rebound powered by innovation, valuations and pharma’s patent cliff

Biotech Growth Trust gives UK investors access to a global biotech sector where Geoffrey Hsu sees a rare combination of scientific innovation, attractive valuations, supportive regulation and renewed M&A momentum...
Verici Dx Plc

Verici Dx strengthens the case for RNA-based kidney transplant diagnostics

Verici Dx is using multicentre clinical data to support RNA-based diagnostics for kidney transplant risk assessment...
Genflow Biosciences Plc

Gene research sharpens the case for targeted biotechnology

Genflow’s focus on SIRT6 highlights how gene science is shaping more targeted approaches to ageing and age-related disease...
EDX Medical Group plc

EDX Medical builds momentum around precision cancer testing

EDX Medical is advancing precision cancer diagnostics through large-scale prostate testing in Scotland, AIM market access and a wider commercial rollout of disease detection products...
Cizzle Biotechnology Holdings plc

Cizzle Bio sharpens focus on earlier lung cancer detection

Cizzle Bio is advancing a minimally invasive blood test aimed at helping lung cancer be detected earlier...
BIOG

Turning scientific breakthroughs into investable commercial opportunities

Scientific breakthroughs become commercially relevant when strong research is matched with scalable infrastructure, business discipline and a clear route to adoption...
BIOG

Why biotech cycles can open timely growth opportunities

Biotech cycles can create attractive opportunities when lower valuations meet advancing science, upcoming clinical milestones, and strong strategic demand from large pharmaceutical companies...
Verici Dx Plc

Verici Dx gains nationwide access for kidney transplant test

Verici Dx has secured New York State approval for Tutivia, giving the kidney transplant rejection risk test nationwide US access...

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

BIOG

Biotech Growth Trust portfolio company AtaiBeckley to be acquired by Eli Lilly

Eli Lilly’s proposed acquisition of AtaiBeckley values the biotechnology company at up to $3.8 billion, including contingent milestone payments. The transaction is the latest in a series of portfolio acquisitions contributing to BIOG’s performance...
EDX Medical Group

EDX Medical Group Targets More Than £2 Million From New Employee Health Screening Service (video)

Chief Scientific Officer Sir Chris Evans explains how its on-site testing model, multi-biomarker panels and personalised reports could help employers identify health risks earlier while reducing disruption and absenteeism...
EDX Medical Group plc

EDX Medical builds scale through Scottish Prostate Cancer Testing programme

EDX Medical is expanding its role in a 25,000-participant Scottish programme testing a more targeted approach to prostate cancer detection...
CTEC

Convatec names NED and outlines CFO transition

Convatec has outlined finance leadership changes, appointed Tobias Hestler as a Non-Executive Director and reaffirmed its 2026 expectations...
CIZ

Cizzle Biotechnology reports US accreditation and patent progress in H1 2026

Cizzle Biotechnology entered its commercialisation phase during the first half of 2026 after securing CLIA accreditation for its CIZ1B early lung cancer test in the U.S. The company also strengthened its North American patent position and increased guaranteed minimum royalty receipts to approximately US$5.9 million...
GNS

Genus expects FY26 profit ahead of consensus after stronger second half

Genus Plc says second-half trading improved, with stronger PIC and ABS performance, and now expects FY26 results moderately ahead of consensus...
BIOG

Biotech Growth Trust gains 19.2% in June, outperforms benchmark

The Biotech Growth Trust delivered a 19.2% NAV return in June, ahead of the NASDAQ Biotechnology Index’s 11.4% gain, supported by positive clinical, regulatory and M&A developments across the sector...
SPI

Spire Healthcare names Debbie White as Chair-designate ahead of Sir Ian Cheshire’s departure

Spire Healthcare has announced that Sir Ian Cheshire will step down as Chair by 30 September 2026 and Debbie White will succeed him...
AstraZeneca

Astrazeneca secures global rights to Zegfrovy in EGFR-mutated lung cancer

Astrazeneca Plc has agreed an exclusive licence with Dizal Pharmaceutical for Zegfrovy, adding a novel oral EGFR inhibitor to its oncology portfolio...
GENF

Genflow Biosciences reports continued SIRT6 progress in first half of 2026

Genflow Biosciences reported positive interim and three-month follow-up results from its SLAB canine trial, expanded animal health partnerships, secured a fully funded LNP collaboration with Acuitas Therapeutics and strengthened its SIRT6 patent portfolio...
GSK plc

GSK reports positive interim AZUR-1 results for Jemperli in rectal cancer

GSK has reported positive interim AZUR-1 results for Jemperli in dMMR/MSI-H locally advanced rectal cancer, with the study meeting its primary objective...
AstraZeneca

AstraZeneca and Ionis’ Wainua misses Phase III ATTR-CM trial endpoint

The CARDIO-TTRansform Phase III trial1 for AstraZeneca and Ionis' Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy.....
Biotech Growth Trust

Biotech Growth Trust: The biotech rebound powered by innovation, valuations and pharma’s patent cliff

Biotech Growth Trust gives UK investors access to a global biotech sector where Geoffrey Hsu sees a rare combination of scientific innovation, attractive valuations, supportive regulation and renewed M&A momentum...
Verici Dx Plc

Verici Dx strengthens the case for RNA-based kidney transplant diagnostics

Verici Dx is using multicentre clinical data to support RNA-based diagnostics for kidney transplant risk assessment...
Genflow Biosciences Plc

Gene research sharpens the case for targeted biotechnology

Genflow’s focus on SIRT6 highlights how gene science is shaping more targeted approaches to ageing and age-related disease...
EDX Medical Group plc

EDX Medical builds momentum around precision cancer testing

EDX Medical is advancing precision cancer diagnostics through large-scale prostate testing in Scotland, AIM market access and a wider commercial rollout of disease detection products...
Cizzle Biotechnology Holdings plc

Cizzle Bio sharpens focus on earlier lung cancer detection

Cizzle Bio is advancing a minimally invasive blood test aimed at helping lung cancer be detected earlier...
BIOG

Turning scientific breakthroughs into investable commercial opportunities

Scientific breakthroughs become commercially relevant when strong research is matched with scalable infrastructure, business discipline and a clear route to adoption...
BIOG

Why biotech cycles can open timely growth opportunities

Biotech cycles can create attractive opportunities when lower valuations meet advancing science, upcoming clinical milestones, and strong strategic demand from large pharmaceutical companies...
Verici Dx Plc

Verici Dx gains nationwide access for kidney transplant test

Verici Dx has secured New York State approval for Tutivia, giving the kidney transplant rejection risk test nationwide US access...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple